BioSpace News Archive

Amber Specialty Pharmacy, an innovator and leader in the specialty pharmacy industry, has been selected as one of only two pharmacies nationally selected by Aimmune Therapeutics, a Nestlé Health Science company, to support the launch of VOWST.

ExThera announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application for ExThera’s OncoBindTM extracorporeal blood filter procedure, intended to remove Circulating Tumor Cells (CTCs) from the bloodstream of patients suffering from Pancreatic Ductal Adenocarcinoma (PDAC).

Rhythm Pharmaceuticals, Inc. announced that on July 10, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 38,955 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 25,970 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 12,985 shares of its common stock.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its second quarter 2023 financial results on Wednesday, August 2, 2023.

Iovance Biotherapeutics, Inc. announced the closing of an underwritten public offering of 23,000,000 shares of its common stock at a public offering price of $7.50 per share.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended May 31, 2023, and provided a corporate update.

ObsEva SA announced that it has recovered full worldwide rights on nolasiban, a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing embryo transfer after in vitro fertilization, following the termination of its sub-licensing agreement with Yuyuan BioScience.

Pharming Group N.V. confirms it will report its preliminary second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.

EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces the final closing of a Series A financing.

Calliditas Therapeutics AB announced interim data from the proof-of-concept Phase 2 trial in patients with squamous cell carcinoma of the head and neck with its lead NOX 1 and 4 inhibitor product candidate, setanaxib.